Interim Financial Result to be Announced 26 November 2020

5 November 2020

INTERM FINANCIAL RESULT TO BE ANNOUNCED 26 NOVEMBER 2020

Pacific Edge Limited (NZX:PEB) advises that its half year results for the six months ending 30 September 2020 will
be released on Thursday 26 November 2020, prior to 10am.

This will be followed by an Investor and Analyst conference call at 10.30am (NZST). This investor briefing will be
available via a webcast (presentation slides and audio only) or ‘audio only’ service. Please follow the instructions
outlined below to access the event.

Webcast Instructions
To join the investor briefing online, click on the link below to attend the presentation from your laptop, tablet
or mobile device. Audio will stream through your selected device, so be sure to have headphones or your volume
turned up. If you have technical difficulties, please click the “Listen by Phone” button on the webcast player and
dial the number provided. A full replay of the presentation will be available at the same link shortly after the
conclusion of the live presentation.

To attend the webcast, please register at the folliowing link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1390291&tp_key=bc89e03003

Audio only – Participant Access Instructions
For the ‘audio only’ option, you can access the investor briefing from your phone. Please join the briefing 5-10
minutes prior to the start time. Please provide your details when prompted and the event passcode: 703463.

New Zealand, toll free: 0800 423 972
New Zealand, Auckland: +64 (0)9 9133 624
Australia, toll free: 1800 590 693
Australia, Brisbane: +61 (0)7 3105 0937
Australia, Melbourne: +61 (0)3 8317 0929
Australia, Sydney: +61 (0)2 9193 3719
USA/Canada: 866-519-2796
USA, Los Angeles: +1 323-794-2095
Singapore, toll free: 800 186 5106
Singapore, local: +65 6320 9041
Hong Kong, toll free: 800 961 113
Hong Kong, local: +852 3008 1533

Questions
Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when
prompted.

The webcast will be available at the above link for 12 months following the event.

Media are invited to contact the company directly for an interview with management.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley
on 03 479 5807 or stacey.stanley@pelnz.com.


ENDS

5 November 2020
Approved for release by:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its non-invasive, simple
to use and accurate Cxbladder tests enable the detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder provides actionable results and better detection and management of urothelial cancer. The company
is developing and commercialising its range of Cxbladder tests globally and has two wholly owned accredited laboratories in
New Zealand and the USA. The company’s products have been tested and validated in multiple international clinical studies.

ABOUT Cxbladder Triage
Cxbladder Triage accurately identifies patients with haematuria who have a low probability of bladder cancer and may not
require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary
evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients
who have a low probability of having urothelial cancer.

ABOUT Cxbladder Detect
Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an
effective adjunct to cystoscopy. Is often used in conjunction with Cxbladder Triage to provide greater rule-out and resolution
of patients who have UC.

ABOUT Cxbladder Monitor
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
cancer. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.